Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2012

View Archived Issues

New product has antidiabetic and antiobesity effects in various animal models

Researchers provide further data on briakinumab efficacy

Addex provides promising topline data from phase IIa trial in levodopa-induced dyskinesia

Gene expression-based MAMPS for the prognosis of breast cancer

Novel naphthoquinones designed in China

Novel GPR119 receptor agonists prepared by Lupin

First-in-human trial of H1N1 influenza vaccine using iBioLaunch technology completed

Taisho presents novel sodium/glucose cotransporter 1 inhibitors

New PUFA metabolites patented by University of Tokyo

Phase I trial commences for candidate ADHD drug

NicOx enters option agreement for acquisition

Corcept Therapeutics announces launch plan

CSL prepares novel humanized IL-3R-alpha-directed antibodies

MDCO-216 as a new reverse cholesterol transport inducer

New monoamine reuptake inhibitors patented

New ICAM-1-targeted antibodies disclosed by MedImmune

Immunovative Therapies patents novel Th1/killer cells

Ajinomoto set to begin marketing certain Marzulene formulations in Japan

Starpharma launches two pivotal phase III VivaGel studies

Biotest reports promising preclinical data on BT-062

Daiichi Sankyo seeks line extension for denosumab in Japan

Daiichi Sankyo to develop narcotic analgesic for Japanese market

FDA committee issues recommendation for Marqibo

Emergent BioSolutions receives NIAID grant to advance TB vaccine candidate

Scottish university receives grant to investigate spread of leukemia in the blood

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...